DM
FDMT icon

Deerfield Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Deerfield Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,821
Closed -$281K – 484
2024
Q1 		$281K Buy
+8,821
New +$225K ﹤0.01% 271
2023
Q4 		– Sell
-650,000
Closed -$8.27M – 227
2023
Q3 		$8.27M Hold
650,000
– – 0.18% 62
2023
Q2 		$11.7M Buy
+650,000
New +$12M 0.25% 66
2021
Q2 		– Sell
-150,000
Closed -$6.51M – 150
2021
Q1 		$6.51M Hold
150,000
– – 0.14% 114
2020
Q4 		$6.22M Buy
+150,000
New +$6.19M 0.12% 116

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management's FDMT Position: Q2 2024 in Review

Deerfield Management sold out of 4D Molecular Therapeutics (FDMT) in Q2 2024, closing a stake of 8,821 shares — an estimated $281K sold.

Deerfield Management first reported a position in FDMT in Q4 2020 and held it in 5 quarters. The position peaked at $11.7M in Q2 2023. 143 funds tracked by Wall St. Rank hold FDMT as of Q2 2024.

  • Deerfield Management reported no remaining 4D Molecular Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Deerfield Management sold 8,821 4D Molecular Therapeutics shares in Q2 2024, an estimated $281K.
  • Deerfield Management first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 5 quarters.
  • Deerfield Management's 4D Molecular Therapeutics position peaked at $11.7M in Q2 2023.
  • 143 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2024.

Based on Deerfield Management's 13F filing for Q2 2024, filed 14 Aug 2024.